Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuroendocrine tumors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    198 result(s) found for: Neuroendocrine tumors. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-023827-34 Sponsor Protocol Number: 1585/10 Start Date*: 2011-05-02
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PHASE III CLINICAL TRIAL TO ASSESS THE ADDED ROLE OF 68Ga-DOTANOC PET-CT IN PATIENTS WITH NEUROENDOCRINE TUMORS
    Medical condition: neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052399 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000240-16 Sponsor Protocol Number: 20110106 Start Date*: 2011-06-12
    Sponsor Name:Skånes Onkologiska Klinik, Skåne University Hospital, Lund
    Full Title: A MULTICENTER PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF 177Lu-DOTA-TATE BASED ON KIDNEY-DOSIMETRY IN PATIENTS WITH DISSEMINATED NEUROENDOCRINE TUMORS
    Medical condition: Metastatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001099-13 Sponsor Protocol Number: CRAD001K24133E1 Start Date*: 2012-05-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors
    Medical condition: advanced neuroendocrine tumors of gastrointestinal or lung origin
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003268-11 Sponsor Protocol Number: IEO676 Start Date*: 2019-02-20
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC in patients with somatostatin receptor positive tumors (neuroendocrine tumors)
    Medical condition: Neuroendocrine tumors in progression of disease and not suitable to additional treatments, positive to SSTR
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004313-13 Sponsor Protocol Number: 20121001 Start Date*: 2013-01-22
    Sponsor Name:Skåne University Hospital, Dept of Oncology
    Full Title: A prospective study of the use of 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.
    Medical condition: Patients with neuroendocrine tumors, who are going to be diagnosed/evaluated with 68Ga-DOTA-TATE PET/CT instead of standard Octreoscan
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002512-14 Sponsor Protocol Number: AK2017-2 Start Date*: 2017-09-04
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002312-13 Sponsor Protocol Number: AK2017-1 Start Date*: 2017-08-25
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003768-30 Sponsor Protocol Number: IEO906 Start Date*: 2019-11-12
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumors
    Medical condition: Pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001613-83 Sponsor Protocol Number: IMMUNeOCT Start Date*: 2017-07-11
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Octreotide LAR in the induction of immunologic response in patient with neuroendocrine tumors: an interventional pharmacological study
    Medical condition: patient with neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005919-30 Sponsor Protocol Number: AK_NEN_DOTA-FDG_21 Start Date*: 2022-09-21
    Sponsor Name:Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet
    Full Title: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms
    Medical condition: Neuroendocrine neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085846 Duodenal neuroendocrine tumor LLT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085958 Small intestine neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002741-21 Sponsor Protocol Number: AAA-Ga-TOC-EU-01 Start Date*: 2014-10-23
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
    Medical condition: Patients with proven gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003927-12 Sponsor Protocol Number: CHUBX2012/28 Start Date*: 2014-03-03
    Sponsor Name:CHU de Bordeaux
    Full Title: Development of an innovative Gallium 68 radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT imaging of neuro-endocrine tumors and preliminary clinical evaluation
    Medical condition: neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000897-65 Sponsor Protocol Number: MN2 Start Date*: 2006-02-20
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Therapy of tumors SSTR2 expressing using somatostatine analogs labeled with 90Y and 177 Lu.
    Medical condition: Diagnosis of tumor classified as expressing SSRT2, the main class of tumors to be included in the study are advanced and metastatic neuroendocrine tumors but also breast, lungs and thyroid cancers...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052399 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006234-16 Sponsor Protocol Number: INT003 Start Date*: 2012-03-27
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refra...
    Medical condition: Patients bearing neuroendocrine tumour expressing somatostatin receptors refractory to conventional therapies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006097-76 Sponsor Protocol Number: LOTUS Start Date*: 2013-01-11
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY OF LOCOREGIONAL TREATMENT WITH TRANSARTERIAL EMBOLIZATION (TAE) FOR LIVER METASTASIS, IN COMBINATION WITH OCTREOTIDE LAR, IN PATIENTS WITH NEUROENDO...
    Medical condition: PATIENTS WITH NEUROENDOCRINE TUMOR AND INOPERABLE LIVER METASTASIS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003640-88 Sponsor Protocol Number: D-FR-01072-004 Start Date*: 2022-01-26
    Sponsor Name:Ariceum Therapeutics GmbH
    Full Title: A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with 177Lu-IPN01072 in an Ipsen-sponsored Clinical Study
    Medical condition: Neuroendocrine tumors (NETs)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000370-30 Sponsor Protocol Number: 20150706 Start Date*: 2015-11-26
    Sponsor Name:Norrlands University Hospital
    Full Title: Diagnosis and follow up of neuroendocrine tumours with 68Ga-DotaToc PET/CT
    Medical condition: Neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003963-58 Sponsor Protocol Number: 5FLUOCT Start Date*: 2005-03-07
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: CONTINOUS INFUSION OF 5-FLUORURACIL PLUS OCTREOTIDE LONG ACTING IN PATIENTS WITH NEUROENDOCRINE ADVANCED NOT SMALL CELL TUMORS
    Medical condition: TREATMENT OF PATIENTS WITH NON SMALL CELL NEUROENDOCRINE TUMORS WITH LOW PROLIFERATIVE ACTIVITY WITHOUT SURGICAL APPROACH
    Disease: Version SOC Term Classification Code Term Level
    10057270 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004019-36 Sponsor Protocol Number: Protocol 2-55-52030-729 Start Date*: 2008-12-01
    Sponsor Name:IPSEN Research and Development, BEAUFOUR IPSEN PHARMA
    Full Title: Open label extension study of lanreotide Autogel 120 mg in patients with non functioning entero-pancreatic endocrine tumour.
    Medical condition: Non functioning entero-pancreatic tumour
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) SK (Completed) BE (Completed) ES (Completed) PL (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005202-10 Sponsor Protocol Number: IEO388 Start Date*: 2016-07-06
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: An open label, single-center, not controlled, exploratory study to develop and evaluate the application of a new technique of radioguided surgery in gastro-entero-pancreatic neuroendocrine tumors (...
    Medical condition: Gastro-entero-pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 19:54:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA